---
document_datetime: 2025-08-12 14:32:21
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/targretin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: targretin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6168503
conversion_datetime: 2025-12-14 22:24:54.421495
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Targretin

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific information after authorisation (archive).

| Applicationnumber    | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation typeIA_IN/ | This was an application for a group of | 11/08/2025                          |                                          | Annex II and                    |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                        | variations. B.II.b.2.cReplacement or addition of a manufacturerresponsibleforimportation and/orbatchrelease-B.I1.b.2.c.1Not includingbatchcontrol/testing-Accepted B.II.b.1Replacementor addition of a manufacturingsiteforpart or all of the manufacturingprocessof thefinished product - B.1I1.b.1.a Secondary packaging site - Accepted                                                                                                                                             |            |            | PL                     | EMA/VR/0000291441   |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------|
| Marketing Authorisation Transfer - H / | -Transfer of a marketing authorisation- transfer ofmarketing authorisationfrom Eisai GmbHtoH.A.C.Pharma                                                                                                                                                                                                                                                                                                                                                                                | 18/03/2025 | 16/04/2025 | SmPC, Labelling and PL | EMA/T/0000256569    |
| Variation typeIA/ EMA/VR/0000246518    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in themanufacturingprocess of the active substance orchangeinthemanufacturer (includingwhererelevantquality control testingsites)ofthe active substance,where noPh.Eur.Certificate of Suitabilityis part of the approveddossier-B.I.a.1.fChanges to quality control testing arrangements for the active substance-replacement or addition of a sitewherebatchcontrol/testingtakes place - Accepted | 27/01/2025 | 16/04/2025 |                        |                     |